Eiger BioPharma slides on failing to meet EUA criteria for COVID-19

Eiger Biopharmaceuticals

06/09/2022 15:21

** Shares of drug developer Eiger BioPharmaceuticals Inc
 EIGR.O  fall 31% to $5.88 - biggest pct loss in more than 4 yrs
    ** U.S. FDA says unsure that EIGR's experimental drug,
peginterferon lambda, meets criteria for emergency use
authorization (EUA) in treatment of patients with
mild-to-moderate COVID-19  urn:newsml:reuters.com:*:nPn9p2TmHa
    ** Drug is in ongoing late-stage trial to treat patients
with severe form of viral hepatitis
    ** FDA adds it is open to consider any new information that
will support an EUA
    ** Co says it will provide additional data 
    ** Including session losses, stock up ~13% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))